gossypol has been researched along with plx4032 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Brewitz, L; Schofield, CJ; Tumber, A; Zhang, X | 1 |
| Merlino, G; Mishra, PJ | 1 |
3 other study(ies) available for gossypol and plx4032
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
Topics: Antibiotics, Antineoplastic; Bleomycin; Dose-Response Relationship, Drug; Drug Compounding; Enzyme Inhibitors; Gossypol; Humans; Mixed Function Oxygenases; Molecular Docking Simulation; Molecular Structure; Small Molecule Libraries; Structure-Activity Relationship | 2020 |
Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genomics; Gossypol; Indoles; Melanoma; Mice; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oncogenes; Proteasome Endopeptidase Complex; Proteolysis; RNA, Messenger; Signal Transduction; Sulfonamides; Vemurafenib | 2016 |